No Increased Risk of Breast Cancer with Estrogen-Alone
Breast Cancer and Postmenopausal Women
Estrogen-alone hormone therapy does not increase the risk of breast cancer in postmenopausal women, according to an updated analysis of the breast cancer findings of the Women's Health Initiative (WHI) Estrogen-Alone Trial.
The results contrast with the previously reported WHI Estrogen plus Progestin Trial, which found an increase in breast cancer over about 5 years among those taking combined hormone therapy.
The WHI is sponsored by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health. The new analysis is published in the April 12 issue of the Journal of the American Medical Association.
Over an average of about 7 years of follow-up, study participants taking estrogen had fewer breast cancer tumors than those in the placebo group. Women in the estrogen group were diagnosed with breast cancer at a rate of 28 per 10,000 participants per year versus a rate of 34 per 10,000 participants per year in the placebo group. The difference in rates of breast cancer (6 per 10,000) between the groups was not statistically significant, meaning it could have occurred by chance.
The new analysis also found that participants taking estrogen had 50 percent more abnormal mammograms that required follow-up and underwent 33 percent (747 compared to 549) more breast biopsies. An abnormal mammogram does not necessarily signal cancer